In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection.
Patients must have histologically confirmed stage I/II (without high risk) colorectal cancer.
Male or female ≥ 18 years of age on the day of signing informed consent.
Patients need to receive surgical resection, and with ctDNA positive prior to resection of colorectal cancer (CRC).
Patients must have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer.
Induction of neoadjuvant systemic therapy prior to resection of CRC.
Patient is pregnant or lactating.
Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.
Singlera Genomics Inc.
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator